You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長江生命科技(00775.HK)上半年純利升14.81%至1億港元
格隆匯 08-03 17:23

格隆匯8月3日丨長江生命科技(00775.HK)公佈中期業績,截至2021年6月30日止6個月,公司實現收入26.38億港元,同比增長10.88%;公司股東權益應占溢利1.00億港元,同比增長14.81%;基本每股溢利1.04 港仙。

儘管 2019 冠狀病毒(COVID-19)帶來種種挑戰,長江生命科技在醫藥研發方面投放更多資源,項目亦按計劃取得穩步進展。

公司位於北美洲及澳洲/新西蘭的主要市場持續面對疫情的相關挑戰。縱使備受封鎖措施、勞工短缺及供應鏈受阻影響,保健產品及農業相關業務仍克服種種困難,錄得銷售增長。

面對 2019 冠狀病毒的相關挑戰,長江生命科技於2021年上半年度在醫藥研發方面進展理想,業績亦有所改善。

長江生命科技的營運模式乃利用來自投資組合的資金,支持醫藥研究發展,公司將繼續持之以恆。我們正積極審視及調配適當資源,致力推動科研項目。隨着疫情逐步緩和,公司將繼續加快 seviprotimut-L、其他癌症疫苗及HalneuronTM 的研發步伐。

在業務經營方面,公司保健產品業務及農業相關業務的根基穩健,加上營運狀況可望逐漸改善,預期業務增長趨勢將會持續。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account